BRANFORD, Conn., Oct. 6, 2010 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced that three scientific abstracts demonstrating the use of the Company's FORE-SIGHT® Absolute Oximeter were presented at the annual conference of the American Academy of Pediatrics in San Francisco, CA, October 2-5, 2010. This meeting is the most comprehensive pediatric meeting in the world and represents the full spectrum of pediatric medical professionals and decision-makers. 

The abstracts presented show the clinical utility of the using FORE-SIGHT technology to monitor preterm infants and other newborns under certain critical conditions.  They demonstrate further that the unique information provided by FORE-SIGHT monitors can guide caregivers in their treatment options.

Thomas M. Patton, President and CEO of CASMED, stated, "We are pleased to report  the publication of additional clinical validation of  the FORE-SIGHT Absolute Oximeter. This research provides further information for clinicians on how FORE-SIGHT can assist them in managing difficult neonatal and pediatric patients."

Abstracts

Said M, Niforatos N, Rais-Bahrami K. Testing a New NIRS Method to Measure Mesenteric Oxygenation of Preterm Infants that Compensates for Meconium and Transitional Stool Interference. Children's National Medical Center and The George Washington University School of Medicine, Washington, D.C. (#10103)

Niforatos N, Said M, Rais-Bahrami K. Cerebral Oximetry Monitoring in Preterm Infants with Respiratory Distress Syndrome. Children's National Medical Center and The George Washington University School of Medicine, Washington, D.C. (#10896)

Chouthai N, Gopal SP, Graham P. Cerebral Oximetry Using Near-Infrared Spectroscopy (NIRS) in Newborns with Hypoxic Ischemic Encephalopathy (HIE) Who Qualify for Clinical Whole Body Hypothermia (WBH). Children's Hospital of Michigan / Wayne State University, Detroit, MI. (#11601)

About CASMED ® - Monitoring What's Vital

CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the first cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for neonates, infants, children and adults. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition.